Investor Presentation H1 2023
51
Investor presentation
First six months of 2023
Phase 2 trial for CagriSema in people with type 2 diabetes was
successfully completed in Q3 2022
Exploratory phase 2a trial of CagriSema in T2D
Cagrilintide 2.4 mg + semaglutide 2.4 mg
Headline trial results
Change in body weight
Mean baseline HbA1c: 8.4%
Mean baseline body weight: 106 kg
Change in HbA1c
R
Cagrilintide 2.4 mg + placebo
1:1:1
Semaglutide 2.4 mg + placebo
Dose escalation
16 weeks
Primary endpoint:
Change from baseline (week 0) to
week 32 in HbA1c
Treatment maintenance
Follow up
16 weeks
5 weeks
Inclusion criteria (92 people):
Type 2 diabetes
Change from baseline (%)
-0.93%
וייווי
-15.6%
-1.79%
-2.18%
Cagrilintide 2.4 mg OW
•
HbA1c 7.5-10.0%
Metformin +/- SGLT2i
BMI ≥27 kg/m2
Semaglutide 2.4 mg OW
CagriSema (2.4 mg semaglutide and 2.4 mg cagrilintide)
In the trial, CagriSema appeared to have a safe and well-tolerated profile
Note: Trial product estimands shown; Trial objective: To compare the effect of co-administered (separate injections) semaglutide and cagrilintide versus semaglutide in subjects with T2D inadequately controlled on metformin with or without SGLT2 inhibitor
T2D: Type 2 diabetes, BMI: body mass index; HbA1c: Glycosylated haemoglobin; OW: Once-weekly
Novo NordiskⓇView entire presentation